Zenas BioPharma (ZBIO) Q3 FY2026 earnings: revenue $10 million
Zenas BioPharma, Inc. (ZBIO) reported revenue of $10 million for Q3 FY2026, the quarter ended 30 September 2026. Net income was -$109 million, and diluted earnings per share $-1.65. The figures are the company's own, from the 10-Q it filed with the SEC on 5 November 2026.
Revenue
$10 million
+900.0% on the quarter
Q2 FY2024Q3 FY2026
Operating margin
-1034.1%
Q2 FY2024Q3 FY2026
Net income
-$109 million
Q2 FY2024Q3 FY2026
Diluted EPS
-$1.65
Q2 FY2024Q3 FY2026
this quarterthe same quarter a year earlierHover a bar for its figure.
What management said
Guidance figures: 7 kept.
FDA accepted obexelimab BLA for IgG4-RD: The BLA was accepted in August and is under active review, with a PDUFA target action date of May 27, 2027.
EMA validated obexelimab marketing application: The EMA validated the MAA for IgG4-RD, confirming essential regulatory elements are included before assessment starts. The application rests on the INDIGO trial and bioequivalence data.
SunStone SLE topline due Q4 2026: Topline results from the Phase 2 SunStone trial of obexelimab in SLE, including a biomarker subset, are anticipated in the fourth quarter of 2026.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Operating cash flow
-58.0
-57.2
-41.1
Capital expenditure
0.0
0.0
0.0
Free cash flow
-58.0
-57.2
-41.1
Free cash flow margin
-579.9%
-5723.7%
n/a
Cash from investing
-19.2
-288
40.0
Cash from financing
57.2
42.1
72.6
+36.0%
-21.2%
Depreciation
0.0
0.0
0.0
0.0%
-63.6%
Share-based compensation
17.3
8.6
7.3
+100.4%
+135.5%
Diluted shares, weighted
66m
63m
42m
+4.8%
+56.9%
Shares outstanding at period end
68m
63m
42m
+7.0%
+60.6%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Shareholders' equity
212
247
196
-14.1%
+8.1%
Debt
299
297
73.0
+0.8%
+310.1%
Operating lease liabilities
0.3
0.0
0.2
+1,345.5%
+76.7%
Other liabilities
163
158
52.4
+3.6%
+211.4%
Total liabilities and equity
675
702
322
-3.8%
+109.7%
Fixed assets
0.0
0.0
0.1
-17.4%
-62.0%
Investments
469
477
186
-1.7%
+152.3%
Cash and equivalents
178
197
116
-9.6%
+53.8%
Other assets
28.1
27.8
20.4
+1.2%
+38.0%
Total assets
675
702
322
-3.8%
+109.7%
Questions
What was Zenas BioPharma's revenue in Q3 FY2026?
Zenas BioPharma (ZBIO) reported revenue of $10 million for Q3 FY2026, the quarter ended 30 September 2026.
How much did Zenas BioPharma earn in Q3 FY2026?
Net loss for Q3 FY2026 was $109 million, and the diluted loss per share $1.65.
When did Zenas BioPharma report Q3 FY2026 results?
Zenas BioPharma filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 5 November 2026.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 30 September 2026, filed 5 November 2026: the filing.